Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Retained Earnings (2020 - 2025)

Mereo BioPharma (MREO) has disclosed Retained Earnings for 6 consecutive years, with -$10.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Retained Earnings rose 1.75% to -$10.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$10.9 million, a 1.75% increase, with the full-year FY2024 number at -$462.9 million, down 10.31% from a year prior.
  • Retained Earnings was -$10.9 million for Q3 2025 at Mereo BioPharma, up from -$486.6 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$10.9 million in Q3 2025 to a low of -$486.6 million in Q2 2025.
  • A 5-year average of -$311.5 million and a median of -$412.1 million in 2022 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: crashed 6162.11% in 2021, then increased 1.75% in 2025.
  • Mereo BioPharma's Retained Earnings stood at -$400.3 million in 2021, then dropped by 1.06% to -$404.6 million in 2022, then decreased by 3.72% to -$419.6 million in 2023, then decreased by 10.31% to -$462.9 million in 2024, then skyrocketed by 97.64% to -$10.9 million in 2025.
  • Per Business Quant, the three most recent readings for MREO's Retained Earnings are -$10.9 million (Q3 2025), -$486.6 million (Q2 2025), and -$472.0 million (Q1 2025).